NALOXONE HYDROCHLORIDE
| Brand name | RIVIVE |
|---|---|
| Active ingredient | NALOXONE HYDROCHLORIDE |
| Strength | 3MG/SPRAY |
| Dosage form | SPRAY, METERED |
| Route | NASAL |
| Modality | Small molecule |
| FDA approval | July 2023 |
| Marketing status | OTC |
| Patent | Expires | Type |
|---|---|---|
| 12458591 | May 2032 | use U-3671 |
| 11020343 | May 2032 | use U-3671 |
| 11806428 | May 2032 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.